摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氰基-3-乙氧基-3-氧代-1-丙烯-2-醇钠 | 627076-29-3

中文名称
1-氰基-3-乙氧基-3-氧代-1-丙烯-2-醇钠
中文别名
氰基丙酮酸乙酯-烯醇钠
英文名称
2-Propenoic acid, 3-cyano-2-hydroxy-, ethyl ester, sodium salt, (2E)-
英文别名
——
1-氰基-3-乙氧基-3-氧代-1-丙烯-2-醇钠化学式
CAS
627076-29-3
化学式
C6H7NNaO3
mdl
——
分子量
164.11
InChiKey
CVDINRSYFUSYRE-WGCWOXMQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.13
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    70.3
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:727b230fc1414a7745deb1e4d39e814e
查看

文献信息

  • Anti-cytokine heterocyclic compounds
    申请人:Cogan Derek
    公开号:US20050256113A1
    公开(公告)日:2005-11-17
    Disclosed are compounds of formula (I) The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.
    揭示了式(I)的化合物。这些化合物抑制了参与炎症过程的细胞因子的产生,因此可用于治疗涉及炎症的疾病和病理条件,如慢性炎症性疾病。还揭示了制备这些化合物的方法以及包含这些化合物的药物组合物。
  • Amidopyrazole Derivative
    申请人:Kanaya Naoaki
    公开号:US20070219210A1
    公开(公告)日:2007-09-20
    A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar 1 and Ar 2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxy carbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.
    提供了一种血小板凝血抑制剂,它既不抑制COX-1也不抑制COX-2。该抑制剂是由通式(I)表示的化合物:其中Ar1和Ar2独立地表示一个5-或6-成员的芳香杂环基团,可选地取代1至3个取代基,或一个苯基,可选地取代1至3个取代基;R1表示较低的酰基,羧基,较低的烷氧羰基,较低的烷氧基,较低的烷基,可选地取代1或2个取代基的氨基甲酰基,可选地取代1或2个取代基的草酰基,可选地取代1或2个取代基的氧代草酰基,可选地取代1或2个取代基的氨基,可选地取代1或2个取代基的4-至7-成员脂环杂环基团,可选地取代1或2个取代基的苯基,或可选地取代1至3个取代基的5-或6-成员芳香杂环基团;R2表示氢原子,卤素基或类似物。
  • Pyrazole Derivative
    申请人:Kanaya Naoaki
    公开号:US20070254881A1
    公开(公告)日:2007-11-01
    A compound represented by Formula (I): wherein Ar 1 represents Formula (II): Ar 2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.
    提供了一种化合物,其化学式表示为(I):其中Ar1表示化学式(II):Ar2表示5或6成员的芳香杂环基团,可以被取代;X表示化学式(III):其盐或化合物或盐的溶剂。提供了一种有效的血小板聚集抑制剂,它不抑制COX-1和COX-2。
  • AMIDOPYRAZOLE DERIVATIVE
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:EP1698626A1
    公开(公告)日:2006-09-06
    A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.
    提供了一种既不抑制 COX-1 也不抑制 COX-2 的血小板凝固抑制剂。该抑制剂为通式 (I) 所代表的化合物: 其中 Ar1 和 Ar2 独立地代表任选被 1 至 3 个取代基取代的 5 或 6 元芳香杂环基团,或任选被 1 至 3 个取代基取代的苯基;R1 代表低级酰基、羧基、低级烷氧羰基、低级烷氧基、任选被 1 或 2 个取代基取代的低级烷基、任选被 1 或 2 个取代基取代的氨基甲酰基、任选被 1 或 2 个取代基取代的草酰基、任选被 1 或 2 个取代基取代的氨基,任选被 1 或 2 个取代基取代的 4 至 7 元脂环杂环基团,任选被 1 至 3 个取代基取代的苯基,或任选被 1 至 3 个取代基取代的 5 或 6 元芳香杂环基团;R2 代表氢原子、卤素基团或类似物。
  • PYRAZOLE DERIVATIVE
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:EP1785418A1
    公开(公告)日:2007-05-16
    A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.
    由式 (I) 代表的化合物: 其中 Ar1 代表式 (II): Ar2 代表可被取代的 5 或 6 元芳香杂环基团;以及 X 代表式(III): 其盐,或该化合物或其盐的溶液。 本发明提供了一种不抑制 COX-1 和 COX-2 的强效血小板聚集抑制剂。
查看更多